What DeepView Imaging does

DeepView Imaging, a service brand of Precision Prostate Consulting, LLC, is a private Maine-based company that delivers AI-powered second-opinion analysis of prostate MRI scans to patients and healthcare providers via a HIPAA-compliant, self-serve web platform. Its core product is the Prostate MRI Analysis Service, which leverages FDA-cleared, CE-marked, and UKCA-certified AI software (ProstatID, developed by partner Bot Image, Inc.) to analyze standard biparametric or multiparametric MRI scans in approximately 30 minutes, identifying and scoring suspicious lesions, generating AI-assisted PI-RADS assessments, producing 3D prostate segmentation, and delivering color-overlay DICOM visualizations plus a PDF diagnostic report. The company also provides a dedicated provider channel for urologists, radiologists, primary care physicians, and imaging centers, with potential for PACS integration and CPT reimbursement pathways.

The business operates on a direct-to-consumer pay-per-scan model with no referral requirement: $259 USD for a first analysis and $159 USD for subsequent analyses, with payment only collected on successful processing and HSA reimbursement available since the service is not covered by insurance or Medicare. The platform serves two primary patient segments — recently diagnosed patients seeking confirmation before treatment and active surveillance patients tracking longitudinal changes — while the provider channel extends the addressable buyer base to clinical professionals. Geographically, DeepView is positioned to serve the US, EU, and UK markets following its 2025 international regulatory clearances, though actual revenue scale, headcount, and unit volumes are not publicly disclosed.

Name

DeepView Imaging

Legal name

Precision Prostate Consulting, LLC

Website

https://deepviewimaging.com

Company type

Private

Operating status

Operating

Short description

DeepView Imaging, a service brand of Precision Prostate Consulting, LLC, delivers AI-powered second-opinion prostate MRI analysis via a direct-to-consumer web platform for individual patients and a parallel channel for urologists, radiologists, primary care physicians, and imaging centers.

Ownership category

akta.pro rank

Product category

Prostate MRI AI Analysis

SIC

Services-Health Services (8000)

akta.pro primary industry

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Second Opinion & Expert Medical Review Platforms (HLALADAI)

Keywords

• Prostate MRI analysis
• AI medical imaging
• Radiology decision support
• Prostate cancer detection
• Medical image analysis

Headquarters

HQ city

Kennebunk

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Operations

Revenue model

1. Direct MRI Analysis Service: Direct-to-consumer paid service where patients or providers pay per MRI analysis. First analysis priced at $259 USD, subsequent analyses at $159 USD. Payment is only collected if the MRI is processed successfully. Includes detailed PDF diagnostic report and colorized DICOM overlay images. Service is out-of-pocket and not covered by insurance or Medicare, though receipts may be submitted for HSA reimbursement.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

DeepView Imaging operates a direct-access web platform that delivers AI-powered second-opinion analysis of prostate MRI scans. Using the FDA-cleared ProstatID™ AI engine, the service identifies suspicious lesions, assigns cancer probability scores, suggests PI-RADS ratings, and produces color-overlay DICOM visualizations plus a PDF diagnostic report within approximately 30 minutes. It is offered out-of-pocket to individual patients (no referral required) and is also positioned for healthcare providers such as urologists, radiologists, primary care physicians, and imaging centers seeking AI-assisted clinical decision support.

Product overview

DeepView Imaging offers a single unified product: the Prostate MRI Analysis Service, which leverages ProstatID (by Bot Image, Inc.) as its underlying AI engine. The service enables patients and providers to upload prostate MRI scans for AI-powered second-opinion analysis, delivering detailed PDF diagnostic reports with color-overlay DICOM images within approximately 30 minutes. The company operates as a service of Precision Prostate Consulting, LLC, providing direct-to-consumer access to FDA-cleared, CE-marked, and UKCA-certified prostate MRI AI analysis.

Differentiator

Problem solved

Functional benefit

Products and services

• Prostate MRI Analysis Service AI-powered second-opinion analysis service for prostate MRI scans, delivering a detailed PDF diagnostic report with color-overlay DICOM visualizations and 3D prostate volume rendering within approximately 30 minutes of upload. Designed for individual patients (no referral required, out-of-pocket pay-per-use) and for healthcare providers (urologists, radiologists, primary care physicians, imaging centers) seeking AI-assisted clinical decision support for lesion detection, cancer probability scoring, PI-RADS assessment, and longitudinal surveillance tracking. Priced at $259 USD for the first analysis and $159 USD for subsequent analyses, HSA-eligible.

Quantifiable outcome

• 93.6% AUROC performance for prostate cancer identification vs ~85% for conventional MRI interpretation
• +3 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

One partnership is on record.

• Bot Image, Inc.coreTechnology or IntegrationBot Image, Inc. is the developer of ProstatID™, the FDA-cleared AI software used for DeepView Imaging's prostate MRI analysis. DeepView Imaging shares MRI image files (DICOM format) with Bot Image solely for the purpose of performing AI-powered analysis and generating patient reports. Bot Image is contractually obligated to use data only for analysis purposes, maintain appropriate security measures, and comply with applicable privacy laws. This is a core technology partnership where DeepView Imaging acts as a service provider/channel for the ProstatID technology.

Scale indicators6 records

Recent moves3 records

Expansion highlights5 records

Broad incumbents

• Siemens Healthineers: Global MRI vendor with AI-augmented reading tools and a broad radiology informatics portfolio. Comparable as an incumbent that could natively embed prostate MRI AI features in its installed base.
• GE HealthCare: Major MRI scanner vendor with embedded AI interpretation tools across its imaging platforms. Comparable as an incumbent channel for prostate MRI workflows and a potential partner or competitor through native AI offerings.

Direct peers

• iCAD: Developer of ProFound AI for breast and prostate cancer detection on MRI/CT. Comparable in FDA-cleared cancer-imaging AI and clinical decision-support positioning, with overlapping prostate MRI use cases.
• Ezra: Direct-to-consumer AI-assisted full-body MRI screening service. Comparable in DTC go-to-market, AI-augmented imaging interpretation, and self-pay pricing model, though Ezra focuses on whole-body screening rather than prostate-specific second opinions.
• RadNet: Largest US outpatient imaging network, increasingly integrating AI (including prostate MRI) into radiology workflows. Comparable as a channel for prostate MRI AI interpretation at scale, though via in-clinic delivery rather than DTC.
• Bot Image: Developer of ProstatID, the FDA-cleared prostate MRI AI engine that DeepView Imaging distributes as a service. It is the upstream technology provider and most direct comparable in product, though DeepView wraps it in a DTC consumer experience.

Emerging players

• Qure.ai: AI radiology company with cleared products for chest X-ray, head CT, and musculoskeletal imaging, expanding into multi-modality diagnostic AI. Comparable in building clinically validated imaging-AI workflows for radiology decision support.
• Nanox (formerly Zebra Medical Vision): Imaging AI vendor (formerly Zebra Medical Vision, now under Nanox) offering AI-based detection and analytics across multiple imaging modalities. Comparable as a multi-modality radiology AI provider with regulatory clearances.
• Lunit: Korea-based medical AI company with FDA-cleared imaging AI products for cancer detection across mammography, chest X-ray, and other modalities. Comparable as an AI-oncologic-imaging peer expanding into global markets.
• Paige.AI: AI company focused on digital pathology and oncologic imaging. Comparable as an oncology-focused diagnostic AI vendor with FDA breakthrough designation, targeting cancer detection/characterization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xfacebook.com/profile.php?id=61589745483833
• LinkedInlinkedin.com/company/deepview-imaging

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeepView Imaging